At the core of Novigenix’s presentation is the new multimodal capability of Novigenix’s LITOSeek platform, which integrates host immune response with tumor-derived signals from non-invasive liquid biopsy. By combining mRNA immune profiling with cfDNA, Novigenix has developed predictive capabilities that improve the accuracy of forecasting patient outcomes. This approach provides insights into patient heterogeneity and therapy response, uncovering mechanisms of action and resistance, and driving the development of novel treatments.

Dr. Niven Mehra, Associate professor in Medical Oncology at Radboud University and a key opinion leader in immuno-oncology, commented: “The integration of immune profiling with systemic tumor-derived data through Novigenix’s LITOSeekTM platform marks a significant advancement in precision oncology. The ability to capture and analyze both the host immune response and tumor signals in a single, comprehensive model offers a powerful tool for early response detection, prediction of patient outcomes and tailoring therapies to individual patient needs.”

Dr. Pedro Romero, Chief Medical & Scientific Officer at Novigenix, emphasized the company’s vision: “Novigenix has long recognized the critical role of the immune system in cancer. Our approach, which merges AI-driven data analytics with deep biological insights, positions us at the forefront of precision medicine. The combined predictive power of immune and tumor signals both enhances patient outcomes and accelerates the development of new, more effective therapies.”

Brian Hashemi, CEO of Novigenix, stated “AI and large-scale data analytics are critical components in unlocking the full potential of precision medicine. Novigenix’s algorithms analyze vast genomic data alongside cfDNA, creating predictive models that revolutionize cancer treatment with more personalized, effective therapies. Our focus on AI and data analytics is central to Novigenix’s mission to revolutionize cancer treatment and improve patient outcomes globally.”

As Novigenix advances its technologies, the company remains committed to increasing the visibility and adoption of its solutions across the biopharma industry. At ESMO 2024, Novigenix will present the most recent findings on combining whole blood mRNA immune profiling and cfDNA for the early identification of patients without clinical benefit to immune checkpoint inhibitors in metastatic urothelial cancer on Sunday September 15th poster session (poster 2000P).